(3/3) …historical controls. This makes us even more optimistic that AIVITA’s second-generation DC-ATA product, which utilizes antigens from autologous GBM tumor-initiating cells that are self-renewing in cell culture, will yield positive results in our randomized Phase 3 trial.
Follow
Dr. Hans Keirstead
@drhanskeirstead
Laguna Beach, CAJoined June 2017
Dr. Hans Keirstead’s Tweets
(2/3) Despite their negative Ph 3 trial, we are happy to see that their first-generation dendritic cell vaccine loaded with antigen from whole autologous tumor cells was associated with prolonged survival in a subset of GBM patients when compared with a particular subset of…
10
(1/3) Autologous dendritic cells loaded with autologous tumor antigens (DC-ATA) is a promising approach for therapeutic anti-cancer vaccines. We have noted the recent 11/17 announcement and related publications by . …
1
BREAKING NEWS: Moscow is not part of CA48 if you vote for Hans Kirstead twitter.com/drhanskeirstea
This Tweet is unavailable.
5
17
Hey, Orange County--put some education and science into your representation. Vote for twitter.com/drhanskeirstea
This Tweet is unavailable.
1
5
7